22 assets in Appendix Cancer

Therapeutic assets addressing Appendix Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii Appendix Cancer	National Cancer Institute (NCI)	P2	BB (64)
Muamycin Appendix Cancer	National Cancer Institute (NCI)	P2	B (63)
Sodium Thiosulfate Appendix Cancer	National Cancer Institute (NCI)	P2	B (61)
Nilotinib Appendix Cancer	National Cancer Institute (NCI)	P2	B (57)
Floxuridine Appendix Cancer	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Cetuximab Appendix Cancer	Allist Pharmaceuticals, Inc.	P1/2	CCC (48)
Jab-21822 Appendix Cancer	Allist Pharmaceuticals, Inc.	P1/2	CCC (48)
Oxaliplatin Appendix Cancer	National Cancer Institute (NCI)	P1	CC (47)
Adriamycin Appendix Cancer	National Cancer Institute (NCI)	P1	CC (43)
Fluorouracilum Appendix Cancer	National Cancer Institute (NCI)	P1	CC (43)
Certepetide Appendix Cancer	University of California, San Diego	P1	CC (41)
Irinotecan Appendix Cancer	University Hospital, Ghent	P1	CC (41)
[18f]f-resca-g5 Appendix Cancer	RenJi Hospital	N/A	D (30)
[18f]f-resca-rb14 Appendix Cancer	RenJi Hospital	N/A	D (30)
[18F]F-RESCA-RND20 Appendix Cancer	RenJi Hospital	N/A	D (30)
[18F]F-RESCA-T4 Appendix Cancer	RenJi Hospital	N/A	D (30)
[18f]f-resca-wwh347 Appendix Cancer	RenJi Hospital	N/A	D (30)
[68Ga]Ga-DOTA-H2D3 Appendix Cancer	RenJi Hospital	N/A	D (30)
[68ga]ga-nota-g5 Appendix Cancer	RenJi Hospital	N/A	D (30)
[68ga]ga-nota-rnd20 Appendix Cancer	RenJi Hospital	N/A	D (30)
[68ga]ga-nota-t4 Appendix Cancer	RenJi Hospital	N/A	D (30)
[68Ga]Ga-NOTA-WWH347 Appendix Cancer	RenJi Hospital	N/A	D (30)